Written by Freddie Dawson || 7th March 2019 || Regulatory briefing |
The resignation of Food and Drug Administration (FDA) commissioner Scott Gottlieb adds further uncertainty to the future of federal oversight of CBD in the US ...
Restricted content. Do you want to read more?
The data or analysis report you have tried to access is restricted to our subscribers. We invite you to take a free trial below where you will get access to a limited set of our content.
You can find available reports for purchase in our online store . Reports not listed in the store are available under request. If you are interested in a subscription, get in contact to discuss our subscription plans or to upgrade your current access.
Register
Sign up NOW for 7 days FREE TRIAL and access our briefings section
Register Here
Visit store
Check out our reports available for purchase
View reports
CBD-Intel provides premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets.
We provide our clients with the tools to navigate this fast-moving sector, tailor their business strategy, optimise resources and make informed decisions.
